Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
Journal
Nature reviews. Endocrinology
ISSN: 1759-5037
Titre abrégé: Nat Rev Endocrinol
Pays: England
ID NLM: 101500078
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
accepted:
27
07
2023
medline:
13
11
2023
pubmed:
6
9
2023
entrez:
5
9
2023
Statut:
ppublish
Résumé
This Consensus Statement from an international, multidisciplinary workshop sponsored by the Pituitary Society offers evidence-based graded consensus recommendations and key summary points for clinical practice on the diagnosis and management of prolactinomas. Epidemiology and pathogenesis, clinical presentation of disordered pituitary hormone secretion, assessment of hyperprolactinaemia and biochemical evaluation, optimal use of imaging strategies and disease-related complications are addressed. In-depth discussions present the latest evidence on treatment of prolactinoma, including efficacy, adverse effects and options for withdrawal of dopamine agonist therapy, as well as indications for surgery, preoperative medical therapy and radiation therapy. Management of prolactinoma in special situations is discussed, including cystic lesions, mixed growth hormone-secreting and prolactin-secreting adenomas and giant and aggressive prolactinomas. Furthermore, considerations for pregnancy and fertility are outlined, as well as management of prolactinomas in children and adolescents, patients with an underlying psychiatric disorder, postmenopausal women, transgender individuals and patients with chronic kidney disease. The workshop concluded that, although treatment resistance is rare, there is a need for additional therapeutic options to address clinical challenges in treating these patients and a need to facilitate international registries to enable risk stratification and optimization of therapeutic strategies.
Identifiants
pubmed: 37670148
doi: 10.1038/s41574-023-00886-5
pii: 10.1038/s41574-023-00886-5
doi:
Substances chimiques
Dopamine Agonists
0
Prolactin
9002-62-4
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
722-740Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. Springer Nature Limited.
Références
Casanueva, F. F. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265–273 (2006).
Melmed, S. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273–288 (2011).
pubmed: 21296991
Wan, X. Y. et al. Overview of the 2022 WHO classification of pituitary adenomas/pituitary neuroendocrine tumors: clinical practices, controversies, and perspectives. Curr. Med. Sci. 42, 1111–1118 (2022).
pubmed: 36544040
Stiles, C. E., Tetteh-Wayoe, E. T., Bestwick, J., Steeds, R. P. & Drake, W. M. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with cabergoline. J. Clin. Endocrinol. Metab. 104, 523–538 (2018).
Hage, C. & Salvatori, R. Predictors of the response to dopaminergic therapy in patients with prolactinoma. J. Clin. Endocrinol. Metab. 105, dgaa652 (2020).
pubmed: 32930718
Giese, S., Nasi-Kordhishti, I. & Honegger, J. Outcomes of transsphenoidal microsurgery for prolactinomas – a contemporary series of 162 cases. Exp. Clin. Endocrinol. Diabetes 129, 163–171 (2021).
pubmed: 33461233
Yagnik, K. J. et al. Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis. Pituitary 24, 978–988 (2021).
pubmed: 34580821
Lu, J. et al. Surgery and medical treatment in microprolactinoma: a systematic review and meta-analysis. Int. J. Endocrinol. 2021, 9930059 (2021).
pubmed: 34504526
pmcid: 8423556
Zamanipoor Najafabadi, A. H. et al. Surgery as a viable alternative first-line treatment for prolactinoma patients. A systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, e32–e41 (2020).
pubmed: 31665485
Glezer, A. & Bronstein, M. D. Prolactinomas in pregnancy: considerations before conception and during pregnancy. Pituitary 23, 65–69 (2020).
pubmed: 31792668
Luger, A. et al. ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur. J. Endocrinol. 185, G1–G33 (2021).
pubmed: 34425558
Molitch, M. E. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur. J. Endocrinol. 172, R205–R213 (2015).
pubmed: 25805896
di Filippo, L., Doga, M., Resmini, E. & Giustina, A. Hyperprolactinemia and bone. Pituitary 23, 314–321 (2020).
pubmed: 32219718
Burman, P. et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur. J. Endocrinol. 187, 593–605 (2022).
pubmed: 36018781
pmcid: 9513638
Guyatt, G. H. et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br. Med. J. 336, 924–926 (2008).
Swiglo, B. A. et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 93, 666–673 (2008).
pubmed: 18171699
Fleseriu, M. et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 9, 847–875 (2021).
pubmed: 34687601
pmcid: 8743006
Chanson, P. & Maiter, D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101290 (2019).
pubmed: 31326373
Shimon, I. Giant prolactinomas. Neuroendocrinology 109, 51–56 (2019).
pubmed: 30404098
Herman, V., Fagin, J., Gonsky, R., Kovacs, K. & Melmed, S. Clonal origin of pituitary adenomas. J. Clin. Endocrinol. Metab. 71, 1427–1433 (1990).
pubmed: 1977759
Melmed, S. Pituitary-tumor endocrinopathies. N. Engl. J. Med. 382, 937–950 (2020).
pubmed: 32130815
Li, C. et al. Somatic SF3B1 hotspot mutation in prolactinomas. Nat. Commun. 11, 2506 (2020).
pubmed: 32427851
pmcid: 7237453
Brandi, M. L. et al. Multiple endocrine neoplasia type 1: latest insights. Endocr. Rev. 42, 133–170 (2021).
pubmed: 33249439
Salenave, S. et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J. Clin. Endocrinol. Metab. 100, 1177–1186 (2015).
pubmed: 25532043
Le Bras, M. et al. Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. Eur. J. Endocrinol. 185, 863–873 (2021).
pubmed: 34636744
Sonigo, C. et al. Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration. J. Clin. Invest. 122, 3791–3795 (2012).
pubmed: 23006326
pmcid: 3461919
Barber, T. M. et al. Mechanisms of central hypogonadism. Int. J. Mol. Sci. 22, 8217 (2021).
pubmed: 34360982
pmcid: 8348115
Sehemby, M. et al. Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline. J. Clin. Endocrinol. Metab. 105, e4551–e4557 (2020).
Rudman, Y., Duskin-Bitan, H., Masri-Iraqi, H., Akirov, A. & Shimon, I. Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma. Pituitary 25, 882–890 (2022).
pubmed: 36036309
Molitch, M. E. Diagnosis and treatment of pituitary adenomas: a review. J. Am. Med. Assoc. 317, 516–524 (2017).
Peric, B. et al. Obesity and hypercholesterolemia in patients with prolactinomas: could DHEA-S and growth hormone be the missing link? Endocr. Res. 41, 200–206 (2016).
pubmed: 26864960
Pinzone, J. J. et al. Primary medical therapy of micro- and macroprolactinomas in men. J. Clin. Endocrinol. Metab. 85, 3053–3057 (2000).
pubmed: 10999785
Iglesias, P. et al. Giant prolactinoma in men: clinical features and therapeutic outcomes. Horm. Metab. Res. 50, 791–796 (2018).
pubmed: 30396208
Colao, A. et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704–1711 (2004).
pubmed: 15070934
Tirosh, A., Benbassat, C., Lifshitz, A. & Shimon, I. Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18, 108–115 (2015).
pubmed: 24700366
Fleseriu, M. et al. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 3888–3921 (2016).
pubmed: 27736313
Samperi, I., Lithgow, K. & Karavitaki, N. Hyperprolactinaemia. J. Clin. Med. 8, E2203 (2019).
Kaiser, U. & Ho, K. Pituitary physiology and diagnostic evaluation. In Williams Textbook of Endocrinology (eds Melmed, S., Koenig, R., Rosen, C. J., Auchus, R. J. & Goldfine, A, B.) 184–235 (Elsevier, 2019).
Karavitaki, N. et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin. Endocrinol. 65, 524–529 (2006).
Alexopoulou, O. et al. Outcome of pituitary hormone deficits after surgical treatment of nonfunctioning pituitary macroadenomas. Endocrine 73, 166–176 (2021).
pubmed: 33852154
De Sousa, S. M. C. et al. Vasculogenic hyperprolactinemia: severe prolactin excess in association with internal carotid artery aneurysms. Pituitary 20, 676–682 (2017).
pubmed: 28828544
Burke, W. T. et al. Prolactinomas and nonfunctioning adenomas: preoperative diagnosis of tumor type using serum prolactin and tumor size. J. Neurosurg. 133, 321–328 (2019).
Cote, D. J. et al. Oral contraceptive and menopausal hormone therapy use and risk of pituitary adenoma: cohort and case-control analyses. J. Clin. Endocrinol. Metab. 107, e1402–e1412 (2022).
pubmed: 34865056
Schievink, W. I. et al. Hyperprolactinemia due to spontaneous intracranial hypotension. J. Neurosurg. 122, 1020–1025 (2015).
pubmed: 25380110
Tsur, A., Dreyfuss, E., Ness-Abramof, R., Pollack, R. & Cahn, A. Role of cannulated prolactin test in evaluation of hyperprolactinemia – a retrospective study. Endocr. Pract. 26, 1304–1311 (2020).
pubmed: 33471661
Whyte, M. B. et al. Importance of cannulated prolactin test in the definition of hyperprolactinaemia. Pituitary 18, 319–325 (2015).
pubmed: 24879500
Mennella, J. A. & Pepino, M. Y. Short-term effects of alcohol consumption on the hormonal milieu and mood states in nulliparous women. Alcohol 38, 29–36 (2006).
pubmed: 16762689
pmcid: 1772851
Petersenn, S. Biochemical diagnosis in prolactinomas: some caveats. Pituitary 23, 9–15 (2020).
pubmed: 31873848
Delcour, C., Robin, G., Young, J. & Dewailly, D. PCOS and hyperprolactinemia: what do we know in 2019? Clin. Med. Insights Reprod. Health 13, 1179558119871921 (2019).
pubmed: 31523136
pmcid: 6734626
Honegger, J. et al. Diagnosis of primary hypophysitis in Germany. J. Clin. Endocrinol. Metab. 100, 3841–3849 (2015).
pubmed: 26262437
Borba, V. V., Zandman-Goddard, G. & Shoenfeld, Y. Prolactin and autoimmunity: the hormone as an inflammatory cytokine. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101324 (2019).
pubmed: 31564625
Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V. & Melmed, S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 10, 804–826 (2022).
pubmed: 36209758
de Vries, F. et al. Opioids and their endocrine effects: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 105, 1020–1029 (2020).
pubmed: 31511863
Molitch, M. E. Drugs and prolactin. Pituitary 11, 209–218 (2008).
pubmed: 18404390
Zhu, Y. et al. Prolactin levels influenced by antipsychotic drugs in schizophrenia: a systematic review and network meta-analysis. Schizophr. Res. 237, 20–25 (2021).
pubmed: 34481200
Aliberti, L. et al. Hypeprolactinemia: still an insidious diagnosis. Endocrine 72, 928–931 (2021).
pubmed: 32949349
Overgaard, M. & Pedersen, S. M. Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia. Clin. Chem. Lab. Med. 55, 1744–1753 (2017).
pubmed: 28236625
Saleem, M., Martin, H. & Coates, P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin. Biochem. Rev. 39, 3–16 (2018).
pubmed: 30072818
pmcid: 6069739
Wallace, I. R. et al. Ten-year clinical follow-up of a cohort of 51 patients with macroprolactinemia establishes it as a benign variant. J. Clin. Endocrinol. Metab. 95, 3268–3271 (2010).
pubmed: 20427494
Olukoga, A. O. & Kane, J. W. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin. Endocrinol. 51, 119–126 (1999).
Raverot, V. et al. Prolactin immunoassay: does the high-dose hook effect still exist? Pituitary 25, 653–657 (2022).
pubmed: 35793045
Nachtigall, L. B. et al. Physicians’ awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a “Pituitary Society” survey. Pituitary 22, 37–45 (2019).
pubmed: 30456434
pmcid: 6697166
Gallo-Bernal, S. et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease after the use of gadolinium-based contrast agents: a review for the cardiovascular imager. Diagnostics 12, 1816 (2022).
pubmed: 36010167
pmcid: 9406537
Alkabbani, A. G. et al. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? Pituitary 17, 97–102 (2014).
pubmed: 23468127
Varlamov, E. V., Hinojosa-Amaya, J. M. & Fleseriu, M. Magnetic resonance imaging in the management of prolactinomas; a review of the evidence. Pituitary 23, 16–26 (2020).
pubmed: 31659622
Lombardi, M. et al. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Horm. Metab. Res. 46, 939–942 (2014).
pubmed: 25230324
Schlechte, J., Dolan, K., Sherman, B., Chapler, F. & Luciano, A. The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68, 412–418 (1989).
pubmed: 2918052
Hinojosa-Amaya, J. M., Varlamov, E. V., McCartney, S. & Fleseriu, M. Pituitary magnetic resonance imaging use in the posttreatment follow-up of secreting pituitary adenomas. In Pituitary Tumors: A Comprehensive and Interdisciplinary Approach (eds J. Honegger, J., Reincke, M. & Petersenn, S.) 447–455 (Academic Press, 2021).
Kreutz, J. et al. Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology 57, 679–684 (2015).
pubmed: 25845810
Burlacu, M. C., Maiter, D., Duprez, T. & Delgrange, E. T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine 63, 323–331 (2019).
pubmed: 30267354
Dogansen, S. C. et al. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary 21, 347–354 (2018).
pubmed: 29460202
Biagetti, B. et al. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline. Eur. J. Endocrinol. 185, 587–595 (2021).
pubmed: 34374649
Eroukhmanoff, J. et al. MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eur. J. Endocrinol. 176, 323–328 (2017).
pubmed: 28073906
Akinduro, O. O. et al. Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure. World Neurosurg. 129, e686–e694 (2019).
pubmed: 31181361
Kharlip, J., Salvatori, R., Yenokyan, G. & Wand, G. S. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94, 2428–2436 (2009).
pubmed: 19336508
pmcid: 2708963
Xia, M. Y., Lou, X. H., Lin, S. J. & Wu, Z. B. Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis. Endocrine 59, 50–61 (2018).
pubmed: 29043560
Melmed, S. et al. Clinical biology of the pituitary adenoma. Endocr. Rev. 43, 1003–1037 (2022).
pubmed: 35395078
pmcid: 9695123
Kuhn, E., Weinreich, A. A., Biermasz, N. R., Jorgensen, J. O. L. & Chanson, P. Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature. Eur. J. Endocrinol. 185, 99–108 (2021).
pubmed: 33914699
Honegger, J., Nasi-Kordhishti, I., Aboutaha, N. & Giese, S. Surgery for prolactinomas – a better choice? Pituitary 23, 45–51 (2019).
Bashari, W. A. et al. Modern imaging of pituitary adenomas. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101278 (2019).
pubmed: 31208872
Bashari, W. A. et al.
pubmed: 35608811
pmcid: 9345820
Bakker, L. E. H. et al. Implementation of functional imaging using
pubmed: 35616762
pmcid: 9345807
Prior, J. C., Cox, T. A., Fairholm, D., Kostashuk, E. & Nugent, R. Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen. J. Clin. Endocrinol. Metab. 64, 391–394 (1987).
pubmed: 3793856
Akirov, A. & Rudman, Y. The role of aromatase inhibitors in male prolactinoma. J. Clin. Med. 12, 1437 (2023).
pubmed: 36835974
pmcid: 9962537
Burnett-Bowie, S. A., McKay, E. A., Lee, H. & Leder, B. Z. Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels. J. Clin. Endocrinol. Metab. 94, 4785–4792 (2009).
pubmed: 19820017
pmcid: 2795655
Ribeiro, R. S. & Abucham, J. Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment. Eur. J. Endocrinol. 161, 163–169 (2009).
pubmed: 19359408
Salenave, S., Trabado, S., Maione, L., Brailly-Tabard, S. & Young, J. Male acquired hypogonadotropic hypogonadism: diagnosis and treatment. Ann. Endocrinol. 73, 141–146 (2012).
Drincic, A. et al. Men with acquired hypogonadotropic hypogonadism treated with testosterone may be fertile. Pituitary 6, 5–10 (2003).
pubmed: 14674718
Mancini, T., Casanueva, F. F. & Giustina, A. Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37, 67–99 (2008).
pubmed: 18226731
Mazziotti, G. et al. High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary 14, 299–306 (2011).
pubmed: 21301967
Giraldi, E. A. & Ioachimescu, A. G. The role of dopamine agonists in pituitary adenomas. Endocrinol. Metab. Clin. North Am. 49, 453–474 (2020).
pubmed: 32741482
Moraes, A. B., Silva, C. M., Vieira Neto, L. & Gadelha, M. R. Giant prolactinomas: the therapeutic approach. Clin. Endocrinol. 79, 447–456 (2013).
Maiter, D. & Delgrange, E. Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur. J. Endocrinol. 170, R213–R227 (2014).
pubmed: 24536090
Huang, H. Y., Lin, S. J., Zhao, W. G. & Wu, Z. B. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: a quantitative and systematic review. Metab. Brain Dis. 33, 969–976 (2018).
pubmed: 29546691
Lee, Y. et al. Early prediction of long-term response to cabergoline in patients with macroprolactinomas. Endocrinol. Metab. 29, 280–292 (2014).
Tirosh, A., Benbassat, C. & Shimon, I. Short-term decline in prolactin concentrations can predict future prolactin normalization, tumor shrinkage, and time to remission in men with macroprolactinomas. Endocr. Pract. 21, 1240–1247 (2015).
pubmed: 26247115
Johnson, M. D., Woodburn, C. J. & Vance, M. L. Quality of life in patients with a pituitary adenoma. Pituitary 6, 81–87 (2003).
pubmed: 14703017
Duskin-Bitan, H. & Shimon, I. Prolactinomas in males: any differences? Pituitary 23, 52–57 (2020).
pubmed: 31802331
Stumpf, M. A. M. et al. How to manage intolerance to dopamine agonist in patients with prolactinoma. Pituitary 26, 187–196 (2023).
pubmed: 37027090
De Sousa, S. M. C. et al. Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors. J. Clin. Endocrinol. Metab. 105, e108–e118 (2020).
Ioachimescu, A. G., Fleseriu, M., Hoffman, A. R., Vaughan Iii, T. B. & Katznelson, L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur. J. Endocrinol. 180, 31–40 (2019).
pubmed: 30400048
Hinojosa-Amaya, J. M. et al. Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas. Front. Endocrinol. 11, 579606 (2020).
Buchfelder, M., Zhao, Y. & Schlaffer, S. M. Surgery for prolactinomas to date. Neuroendocrinology 109, 77–81 (2019).
pubmed: 30699424
Lam, G., Mehta, V. & Zada, G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. Neurosurg. Focus. 32, E2 (2012).
pubmed: 22655691
Steeds, R. et al. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Clin. Endocrinol. 90, 662–669 (2019).
Souteiro, P., Belo, S. & Carvalho, D. Dopamine agonists in prolactinomas: when to withdraw? Pituitary 23, 38–44 (2020).
pubmed: 31556013
Paepegaey, A. C. et al. Cabergoline tapering is almost always successful in patients with macroprolactinomas. J. Endocr. Soc. 1, 221–230 (2017).
pubmed: 29264479
pmcid: 5686686
Vilar, L. et al. Second attempt of cabergoline withdrawal in patients with prolactinomas after a failed first attempt: is it worthwhile? Front. Endocrinol. 6, 11 (2015).
Kwancharoen, R. et al. Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary 17, 451–456 (2014).
pubmed: 24078319
Greenman, Y. Prolactinomas and menopause: any changes in management? Pituitary 23, 58–64 (2020).
pubmed: 31686376
Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006).
pubmed: 16705142
Primeau, V., Raftopoulos, C. & Maiter, D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur. J. Endocrinol. 166, 779–786 (2012).
pubmed: 22301915
Kreutzer, J. et al. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur. J. Endocrinol. 158, 11–18 (2008).
pubmed: 18166812
Tampourlou, M., Trifanescu, R., Paluzzi, A., Ahmed, S. K. & Karavitaki, N. Therapy of endocrine disease: surgery in microprolactinomas: effectiveness and risks based on contemporary literature. Eur. J. Endocrinol. 175, R89–R96 (2016).
pubmed: 27207245
Baussart, B. et al. Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur. J. Endocrinol. 185, 783–791 (2021).
pubmed: 34605772
Micko, A., Vila, G., Hoftberger, R., Knosp, E. & Wolfsberger, S. Endoscopic transsphenoidal surgery of microprolactinomas: a reappraisal of cure rate based on radiological criteria. Neurosurgery 85, 508–515 (2019).
pubmed: 30169711
Ma, Q. et al. The chance of permanent cure for micro- and macroprolactinomas, medication or surgery? A systematic review and meta-analysis. Front. Endocrinol. 9, 636 (2018).
Wright, K. et al. Determinants of surgical remission in prolactinomas: a systematic review and meta-analysis. World Neurosurg. 154, e349–e369 (2021).
pubmed: 34325023
Losa, M., Mortini, P., Barzaghi, R., Gioia, L. & Giovanelli, M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J. Clin. Endocrinol. Metab. 87, 3180–3186 (2002).
pubmed: 12107221
Osorio, R. C. et al. Correlation between tumor volume and serum prolactin and its effect on surgical outcomes in a cohort of 219 prolactinoma patients. J. Neurosurg. 138, 1669–1679 (2022).
Ikeda, H., Watanabe, K., Tominaga, T. & Yoshimoto, T. Transsphenoidal microsurgical results of female patients with prolactinomas. Clin. Neurol. Neurosurg. 115, 1621–1625 (2013).
pubmed: 23498159
Zielinski, G., Ozdarski, M., Maksymowicz, M., Szamotulska, K. & Witek, P. Prolactinomas: prognostic factors of early remission after transsphenoidal surgery. Front. Endocrinol. 11, 439 (2020).
Abou-Al-Shaar, H. et al. The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus. Pituitary 25, 508–519 (2022).
pubmed: 35467273
Force, B. K. et al. Endoscopic endonasal transsphenoidal surgery for patients with prolactinomas: indications and outcomes. World Neurosurg. 168, e626–e635 (2022).
pubmed: 36270592
Donoho, D. A. & Laws, E. R. Jr. The role of surgery in the management of prolactinomas. Neurosurg. Clin. North Am. 30, 509–514 (2019).
Vroonen, L. et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur. J. Endocrinol. 167, 651–662 (2012).
pubmed: 22918301
Menucci, M., Quinones-Hinojosa, A., Burger, P. & Salvatori, R. Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary 14, 68–74 (2011).
pubmed: 20878243
pmcid: 4612584
Nakhleh, A. et al. Management of cystic prolactinomas: a review. Pituitary 21, 425–430 (2018).
pubmed: 29654440
Yousem, D. M., Arrington, J. A., Zinreich, S. J., Kumar, A. J. & Bryan, R. N. Pituitary adenomas: possible role of bromocriptine in intratumoral hemorrhage. Radiology 170, 239–243 (1989).
pubmed: 2909102
Hage, C. & Salvatori, R. Speed of response to dopaminergic agents in prolactinomas. Endocrine 75, 883–888 (2022).
pubmed: 34846682
Faje, A. et al. Dopamine agonists can reduce cystic prolactinomas. J. Clin. Endocrinol. Metab. 101, 3709–3715 (2016).
pubmed: 27459530
Colao, A. et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325–331 (2003).
pubmed: 12611613
Mazziotti, G. et al. Vertebral fractures in males with prolactinoma. Endocrine 39, 288–293 (2011).
pubmed: 21479837
Shimon, I., Benbassat, C., Tzvetov, G. & Grozinsky-Glasberg, S. Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression. Pituitary 14, 11–15 (2011).
pubmed: 20717729
Shimon, I. et al. Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years. Endocrine 65, 656–661 (2019).
pubmed: 31154607
Delgrange, E., Trouillas, J., Maiter, D., Donckier, J. & Tourniaire, J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J. Clin. Endocrinol. Metab. 82, 2102–2107 (1997).
pubmed: 9215279
Fainstein Day, P. et al. Gender differences in macroprolactinomas: study of clinical features, outcome of patients and Ki-67 expression in tumor tissue. Front. Horm. Res. 38, 50–58 (2010).
pubmed: 20616495
Nishioka, H., Haraoka, J. & Akada, K. Growth potential of prolactinomas in men: is it really different from women?. Surg. Neurol. 59, 386–390 (2003).
pubmed: 12765811
Schaller, B. Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol. Lett. 26, 152–159 (2005).
pubmed: 15855888
Melmed, S. Mechanisms for pituitary tumorigenesis: the plastic pituitary. J. Clin. Invest. 112, 1603–1618 (2003).
pubmed: 14660734
pmcid: 281651
Lasolle, H., Ilie, M. D. & Raverot, G. Aggressive prolactinomas: how to manage? Pituitary 23, 70–77 (2020).
pubmed: 31617128
Raverot, G. et al. Aggressive pituitary tumours and pituitary carcinomas. Nat. Rev. Endocrinol. 17, 671–684 (2021).
pubmed: 34493834
Maiter, D. Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109, 42–50 (2019).
pubmed: 30481756
Raverot, G. et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178, G1–G24 (2018).
pubmed: 29046323
McCormack, A. et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur. J. Endocrinol. 178, 265–276 (2018).
pubmed: 29330228
Losa, M. et al. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J. Neurooncol. 126, 519–525 (2016).
pubmed: 26614517
Lasolle, H. et al. Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur. J. Endocrinol. 176, 769–777 (2017).
pubmed: 28432119
Elbelt, U. et al. Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas – a German survey. J. Clin. Endocrinol. Metab. 105, e660–e675 (2020).
Goichot, B. et al. Should pituitary carcinoma be treated using a NET-like approach? A case of complete remission of a metastatic malignant prolactinoma with multimodal therapy including immunotherapy. Clin. Endocrinol. 98, 633–637 (2023).
Ilie, M. D. et al. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Eur. J. Endocrinol. 187, 685–696 (2022).
pubmed: 36111659
Raverot, G. & Ilie, M. D. Immunotherapy in pituitary carcinomas and aggressive pituitary tumors. Best. Pract. Res. Clin. Endocrinol. Metab. 36, 101712 (2022).
pubmed: 36274025
Zhang, D. et al. Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 104, 1929–1936 (2019).
pubmed: 30624667
Cooper, O. et al. EGFR/ErbB2-targeting lapatinib therapy for aggressive prolactinomas. J. Clin. Endocrinol. Metab. 106, e917–e925 (2021).
pubmed: 33150390
Bazuhair, T., Aleid, B. & Almalki, M. Effect of tamoxifen on the management of dopamine agonist-resistant prolactinomas: a systematic review. Cureus 15, e35171 (2023).
pubmed: 36950000
pmcid: 10029104
Petersenn, S. & Heaney, A. P. Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas. Rev. Endocr. Metab. Disord. 21, 277–286 (2020).
pubmed: 32415583
Casanueva, F. F. et al. Criteria for the definition of pituitary tumor centers of excellence (PTCOE): a Pituitary Society statement. Pituitary 20, 489–498 (2017).
pubmed: 28884415
pmcid: 5606938
Zhong, H. P. et al. Multidisciplinary team efforts improve the surgical outcomes of sellar region lesions during pregnancy. Endocrine 66, 477–484 (2019).
pubmed: 31422527
Sant’ Anna, B. G. et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary 23, 120–128 (2020).
pubmed: 31728906
Martinez de LaPiscina, I. et al. Clinical and genetic characteristics in patients under 30 years with sporadic pituitary adenomas. Eur. J. Endocrinol. 185, 485–496 (2021).
pubmed: 34313605
Tatsi, C. & Stratakis, C. A. Aggressive pituitary tumors in the young and elderly. Rev. Endocr. Metab. Disord. 21, 213–223 (2020).
pubmed: 31912365
Breil, T. et al. Clinical features and response to treatment of prolactinomas in children and adolescents: a retrospective single-centre analysis and review of the literature. Horm. Res. Paediatr. 89, 157–165 (2018).
pubmed: 29455199
Brichta, C. M., Wurm, M., Krebs, A., Schwab, K. O. & van der Werf-Grohmann, N. Start low, go slowly – mental abnormalities in young prolactinoma patients under cabergoline therapy. J. Pediatr. Endocrinol. Metab. 32, 969–977 (2019).
pubmed: 31323004
Hoffmann, A., Adelmann, S., Lohle, K., Claviez, A. & Muller, H. L. Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Eur. J. Pediatr. 177, 125–132 (2018).
pubmed: 29168011
Culpin, E. et al. Pituitary tumour apoplexy within prolactinomas in children: a more aggressive condition? Pituitary 21, 474–479 (2018).
pubmed: 30014342
pmcid: 6132972
Jankowski, P. P. et al. Pituitary tumor apoplexy in adolescents. World Neurosurg. 83, 644–651 (2015).
pubmed: 25527883
McCormack, A. Childhood-onset prolactinomas – should earlier surgery be considered? Clin. Endocrinol. 95, 571–573 (2021).
Chanson, P. Treatments of psychiatric disorders, hyperprolactinemia and dopamine agonists. Best. Pract. Res. Clin. Endocrinol. Metab. 36, 101711 (2022).
pubmed: 36280567
Alosaimi, F. D. et al. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int. J. Psychiatry Clin. Pract. 22, 274–281 (2018).
pubmed: 29334291
Haddad, P. M. & Wieck, A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64, 2291–2314 (2004).
pubmed: 15456328
Chang, S. C., Chen, C. H. & Lu, M. L. Cabergoline-induced psychotic exacerbation in schizophrenic patients. Gen. Hosp. Psychiatry 30, 378–380 (2008).
pubmed: 18585544
Allard, L. et al. Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma. Eur. J. Endocrinol. 183, 221–231 (2020).
pubmed: 32583656
Besag, F. M. C., Vasey, M. J. & Salim, I. Is adjunct aripiprazole effective in treating hyperprolactinemia induced by psychotropic medication? A narrative review. CNS Drugs 35, 507–526 (2021).
pubmed: 33880739
Balint-Peric, L. A. & Prelevic, G. M. Changes in prolactin levels with the menopause: the effects of estrogen/androgen and calcitonin treatment. Gynecol. Endocrinol. 11, 275–280 (1997).
pubmed: 9272425
Karunakaran, S., Page, R. C. & Wass, J. A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. 54, 295–300 (2001).
Santharam, S. et al. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin. Endocrinol. 89, 346–353 (2018).
Indirli, R. et al. Cabergoline withdrawal before and after menopause: outcomes in microprolactinomas. Horm. Cancer 10, 120–127 (2019).
pubmed: 31001736
pmcid: 10355708
Maor, Y. & Berezin, M. Hyperprolactinemia in postmenopausal women. Fertil. Steril. 67, 693–696 (1997).
pubmed: 9093196
Shimon, I. et al. Women with prolactinomas presented at the postmenopausal period. Endocrine 47, 889–894 (2014).
pubmed: 24711223
Santharam, S. et al. Prolactinomas diagnosed in the postmenopausal period: clinical phenotype and outcomes. Clin. Endocrinol. 87, 508–514 (2017).
Dekkers, O. M. et al. Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. Eur. J. Endocrinol. 173, 269–273 (2015).
pubmed: 26012587
Soto-Pedre, E., Newey, P. J., Bevan, J. S. & Leese, G. P. Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study. Endocr. Connect. 6, 580–588 (2017).
pubmed: 28954743
pmcid: 5633062
Hembree, W. C. et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 102, 3869–3903 (2017).
pubmed: 28945902
Nota, N. M. et al. Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons. Andrologia 49, e12666 (2017).
Defreyne, J. et al. Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment. LGBT Health 4, 328–336 (2017).
pubmed: 28880825
Raven, L. M., Guttman-Jones, M. & Muir, C. A. Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment. Endocrine 72, 524–528 (2021).
pubmed: 33398769
Cowden, E. A., Ratcliffe, W. A., Ratcliffe, J. G., Dobbie, J. W. & Kennedy, A. C. Hyperprolactinaemia in renal disease. Clin. Endocrinol. 9, 241–248 (1978).
Hou, S. H., Grossman, S. & Molitch, M. E. Hyperprolactinemia in patients with renal insufficiency and chronic renal failure requiring hemodialysis or chronic ambulatory peritoneal dialysis. Am. J. Kidney Dis. 6, 245–249 (1985).
pubmed: 4050782
Rodriguez-Puyol, D. et al. Molecular heterogeneity of circulating prolactin in chronic uremic men and renal transplant recipients. J. Clin. Endocrinol. Metab. 62, 352–356 (1986).
pubmed: 3079774
Veldhuis, J. D., Iranmanesh, A., Wilkowski, M. J. & Samojlik, E. Neuroendocrine alterations in the somatotropic and lactotropic axes in uremic men. Eur. J. Endocrinol. 131, 489–498 (1994).
pubmed: 7952159
Lo, J. C. et al. Hyperprolactinemia in end-stage renal disease and effects of frequent hemodialysis. Hemodial. Int. 21, 190–196 (2017).
pubmed: 27774730
Weizman, R. et al. Sexual dysfunction associated with hyperprolactinemia in males and females undergoing hemodialysis. Psychosom. Med. 45, 259–269 (1983).
pubmed: 6611804
Schaefer, R. M., Kokot, F., Kuerner, B., Zech, M. & Heidland, A. Normalization of serum prolactin levels in hemodialysis patients on recombinant human erythropoietin. Int. J. Artif. Organs 12, 445–449 (1989).
pubmed: 2767790